Pallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth Prospects [Yahoo! Finance]
Monte Rosa Therapeutics, Inc. (GLUE)
Company Research
Source: Yahoo! Finance
quarter, Pallas Capital Advisors acquired a new position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) through the purchase of 13,182 shares of the company's stock. According to the latest filing with the SEC, the firm's investment in the company is approximately $59,000. There are many advocates for Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), and it comes as no surprise. The company has managed to strike another deal with Novartis, which involves both companies developing molecular glue degraders for immune-mediated disorders. This is yet another major highlight as it brings forth $120 million in proceeds, along with the potential to generate $5.7 billion in milestone payments. Why Core Scientific Inc. (CORZ) Skyrocketed Today If that weren't already a strong case, Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has been awarded IND clearance from the FDA to accelerate MRT-8102, a second molecular glue degrader. As long as the company executes its initiatives successfully, we hav
Show less
Read more
Impact Snapshot
Event Time:
GLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLUE alerts
High impacting Monte Rosa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GLUE
News
- Monte Rosa: Looking Mispriced After Big Pharma Validation [Seeking Alpha]Seeking Alpha
- Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic DiseasesGlobeNewswire
- Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Wells Fargo & Company from $10.00 to $13.00. They now have an "equal weight" rating on the stock.MarketBeat
- Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business UpdatesGlobeNewswire
GLUE
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form SCHEDULE
- GLUE's page on the SEC website